Comparative Pharmacology
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus MYTESI.
Head-to-head clinical analysis: DIPHENOXYLATE HYDROCHLORIDE W ATROPINE SULFATE versus MYTESI.
DIPHENOXYLATE HYDROCHLORIDE W/ ATROPINE SULFATE vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diphenoxylate acts as an opioid agonist on mu-opioid receptors in the gastrointestinal tract, reducing peristalsis and increasing intestinal transit time. Atropine sulfate is added at subtherapeutic doses to deter abuse by causing unpleasant anticholinergic effects at high doses.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
2.5-5 mg (diphenoxylate) orally 4 times daily until diarrhea controlled; maximum 20 mg/day (diphenoxylate).
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Diphenoxylate: terminal half-life of 2.9-5.8 hours (active metabolite difenoxin: 12-14 hours). Atropine: terminal half-life of 2-4 hours. Clinical context: The long half-life of difenoxin contributes to sustained antidiarrheal effect.
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Diphenoxylate is excreted primarily in feces (via biliary elimination) as the active metabolite difenoxin and its conjugates; approximately 14% is excreted renally as unchanged drug and metabolites. Atropine is excreted renally (30-50% unchanged) and partially in feces.
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
Antidiarrheal
Antidiarrheal